Biocon Q2 profit halves to ₹41 crore as delayed shipments weigh on margins
Biocon moved higher in a quarterly results development for Q2FY27.
· BS Companies
Biocon's Q2FY27 net profit fell 52 per cent to ₹41 crore as delayed shipments worth $20 million hit margins, while revenue rose 2 per cent to ₹4,389 crore.
Key facts
- Period
- Q2FY27
The analysis
Biocon reported ₹41 crore and ₹4,389 crore for Q2FY27, with movement of 2% and 52% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.4% on the day at ₹344.45, and has returned -18.4% over three months. It sits 22% below its 52-week high. The pharma & healthcare sector has moved +1.0% over the same period, so Biocon is running 19.4 points behind its peers.
For Biocon, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Biocon (BIOCON), in Pharma & Healthcare.
- Over three months: Biocon -18.4% against Pharma & Healthcare +1.0% (19.4 points behind).
- Trading well above normal today: Biocon at 2.9 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| BioconBIOCON · Pharma & Healthcare | ₹344.45 | +0.4% | -7.1% | -18.4% | -21.8% | 2.9× | — |
Pharma & Healthcare
1M +2.6% · 3M +1.0%
Biocon
Prices as of 4 Nov 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Alembic Pharma shares hit 20% upper circuit after 81% YoY rise in Q2 PAT
Zydus Lifesciences Q2 results: Net profit falls 26.6% to ₹925.5 crore
Lupin Q2 results: Net profit falls 22% to ₹1,155 cr, revenue at ₹7,827 cr
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Q2 Results Live: Pfizer's One-Time Gain Lifts Profit; SBI Asset Quality Improves; Solar Industries Profit Zooms 79%